Disease Focus: Colon Cancer
TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers
A Phase 1b/2 Trial of the Anti-CD47 Antibody Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer
Forty Seven, Inc. has developed an antibody therapy to block a protein called CD47 that is found on the surface of cancer cells. CD47 acts as a ‘don’t eat me’ signal that tells immune cells not to eliminate the cancer cells. When this ‘don’t eat me’ signal is blocked by the antibody, the cancer cells […]
A Novel Approach to Eradicate Cancer Stem Cells
Research Objective The outcome is a therapeutic candidate ready for Investigational New Drug (IND)-enabling studies to target a central hub of stemness pathways of cancer stem cells (CSC) maintenance and self-renewal Impact To date, the majority of metastatic cancers remain incurable, because CSCs that can grow new tumors evades current therapy. The proposed studies aim […]
A Novel Approach to Eradicate Cancer Stem Cells
Research Objective The outcome is a therapeutic candidate ready for Investigational New Drug (IND)-enabling studies to target a central hub of stemness pathways of cancer stem cells (CSC) maintenance and self-renewal Impact To date, the majority of metastatic cancers remain incurable, because CSCs that can grow new tumors evades current therapy. The proposed studies aim […]
TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers
Therapeutic Candidate or Device TACH101 is a first-in-class small molecule inhibitor of KDM4 histone demethylase, an epigenetic modifier important for cancer stem cell proliferation. Indication Colorectal Cancer Therapeutic Mechanism TACH101 is intended to target colorectal cancer (CRC) stem cells as well as the bulk tumor by inhibiting proliferation. In CRC animal models, TACH101 treatment reduced […]
A Phase 1b/2 Trial of the Anti-CD47 Antibody Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer
Therapeutic Candidate or Device The treatment is two drugs: Hu5F9-G4 and cetuximab. These are antibodies, which are engineered drugs that eliminate cancers using the immune system. Indication Patients with advanced colon cancer that have a genetic mutation in the KRAS gene and those without the KRAS genetic mutation. Therapeutic Mechanism This treatment targets cancer stem […]